Highlights 3SBio Inc.

Equities

1530

KYG8875G1029

Market Closed - Hong Kong S.E. Other stock markets 09:08:22 10/05/2024 BST			5-day change	1st Jan Change
6.74 ^HKD	-0.15%		-0.88%	-10.37%

04-22	3Sbio Inc. Announces Management Changes	CI
04-15	3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia	04-15	MT
3SBio Inc. Approves Recombinant Human Thrombopoietin Injection for Pediatric ITP Indication	04-12	CI
3SBio Inc. commences an Equity Buyback for 243,892,041 shares, representing 10% of its issued share capital, under the authorization approved on June 20, 2023.	03-27	CI
3SBio's 2023 Profit Falls 19%, EPS Misses Estimates	03-21	MT
3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on August 05, 2024	03-20	CI
3SBio Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
China's NMPA Gives 3SBio Permission to Sell Anti-Dandruff Product	01-08	MT
Mandi Foam of 3SBio Inc. Approves for Market Launch	01-08	CI
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China	11-02	MT
3SBio's H1 Attributable Profit Rises, Beats EPS Estimates	25/08/23	MT
3SBio Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	24/08/23	CI
3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market	05/07/23	CI
3SBio Inc.'s Equity Buyback announced on July 15, 2022, has expired.	19/06/23	CI
3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2022, Payable on 11 July 2023	22/05/23	CI
3SBio Inc. Announces First Patient Enrolled in the Trial of Phase III Clinical Study of Recombinant Human Thrombopoietin Injection	22/05/23	CI
3Sbio Inc. Announces That the First Patient Recently Been Enrolled in the Trial of Phase Iii Clinical Study of Recombinant Human Thrombopoietin Injection	22/05/23	CI
3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2022, Payable on July 11, 2023	21/03/23	CI
3SBio Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	21/03/23	CI
3Sbio Inc. announces Termination of Exclusive License Agreement with Astrazeneca in Respect of Byetta and Bydureon	28/02/23	CI
3SBIO's H1 Net Profit Rises 6.2%	25/08/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights 3SBio Inc.

Equities

1530

KYG8875G1029

Highlights

Filters